Medicare's GLP-1 Bridge Launched July 1. DPC Physicians Can Write the Prescriptions Without Being Enrolled in Medicare.

Industry News by DPC Insider
#GLP-1#Medicare#obesity#weight-management#cms#foundayo
Sources: Medicare GLP-1 Bridge — CMS · Information for Providers — Medicare GLP-1 Bridge, CMS · Medicare GLP-1 Bridge: Information for Prescribers — CMS (PDF) · GLP-1 Weight-Loss Drug Demonstration Begins July 2026 — Medicare Rights Center · FDA approves Lilly's Foundayo (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions — Eli Lilly investor release · As Americans go direct with GLP-1 prescriptions, Walmart, Costco, Amazon will be big weight-loss winners — CNBC, August 1, 2026 · Innovation Insight: Affordability of GLP-1s Takes Next Step with BALANCE Model RFAs — CMS Innovation Center

Visit-by-visit payment is a poor fit for primary care — that is the operating premise behind DPC. Starting July 1, three GLP-1 medications are covered under a new CMS demonstration for eligible Medicare Part D patients — and the prescribing physician doesn’t need to be enrolled in Medicare to write those prescriptions, consistent with the Part D prescriber rule that has been in place since 2019.

The vehicle is the Medicare GLP-1 Bridge, a short-term CMS demonstration that covers three GLP-1 medications for eligible Part D beneficiaries at a $50 monthly patient copay. It launched July 1, 2026 and runs through December 31, 2027. What the program does not require is that the prescribing physician be enrolled in Medicare.

What the Bridge covers

Three drugs are in the Bridge formulary:

  • Wegovy (semaglutide), in both injectable and tablet forms, from Novo Nordisk
  • Zepbound (tirzepatide, KwikPen), from Eli Lilly
  • Foundayo (orforglipron), also from Eli Lilly — the oral GLP-1 pill FDA approved April 1, 2026 that can be taken any time of day without food or water restrictions

The $50 copay applies per fill (28- or 30-day supply). CMS manages the program through a single central processor that handles prior authorizations, claims adjudication, and pharmacy payment. Part D sponsors don’t carry financial risk for Bridge claims. A patient whose Part D plan doesn’t ordinarily cover weight-management GLP-1s can still access the Bridge.

The prescriber rule

Here is the relevant passage from CMS’s provider guidance: “For the Medicare GLP-1 Bridge, as in the Part D program, a provider does not need to be enrolled in Medicare in order to write a prescription or submit a prior authorization request for products provided under the Medicare GLP-1 Bridge to an eligible beneficiary.”

The one Bridge-specific prescriber disqualifier CMS names: the prescriber must not appear on the CMS Preclusion List. The published criteria for Preclusion List placement do not include opt-out status.

This is consistent with how Medicare Part D prescription coverage has worked since 2019, when CMS rescinded an earlier prescriber enrollment requirement and replaced it with the Preclusion List. Part D coverage of a drug does not require the prescribing physician to be enrolled in Part B. The significance of the CMS guidance is that it removes ambiguity for a new program that many DPC physicians might have assumed they were excluded from. They weren’t. They’re in.

Who among your patients qualifies

The CMS prescriber guide sets four eligibility conditions for patients:

  1. Enrolled in an eligible Medicare Part D plan
  2. Has not previously received a GLP-1 through their Medicare Part D plan
  3. Does not have a diagnosis of type 2 diabetes, moderate-to-severe sleep apnea, or metabolic dysfunction-associated steatohepatitis (MASH)
  4. Meets clinical criteria at the time GLP-1 therapy was initiated: age 18 or older, and either a BMI of 35 or higher; or a BMI of 30 or higher with a qualifying comorbidity such as heart failure with preserved ejection fraction, uncontrolled hypertension, or CKD stage 3a or above; or a BMI of 27 or higher with pre-diabetes, prior heart attack, prior stroke, or symptomatic peripheral artery disease

The clinical indication is weight management — obesity under the E66 diagnosis code family. Patients you might expect to qualify may not: someone who received Ozempic through Part D for diabetes is outside the Bridge. So is a patient who was already accessing a GLP-1 for any Part D-covered indication. The Bridge’s eligibility pathway is specific.

That said, there is a meaningful patient population here. DPC practices that serve Medicare Part D patients who meet the weight and clinical criteria, haven’t previously received a GLP-1 through their Part D plan, and don’t have a disqualifying diagnosis are the patients the Bridge is designed to reach.

How the prescription works

The prior authorization under the Bridge is prospective — the patient cannot fill the prescription until PA is approved. The sequence, per the CMS prescriber guide:

  1. Transmit the prescription to the pharmacy using your standard process. To direct the claim to the Bridge rather than the patient’s Part D plan, CMS recommends including an E66-family obesity diagnosis code and the note “SEND TO BRIDGE FOR WEIGHT MANAGEMENT” in the prescription’s notes field.
  2. The pharmacy attempts to process the claim and it is initially denied.
  3. The pharmacy sends you a prior authorization request.
  4. You submit attestation of the clinical criteria — the patient’s diagnosis, BMI, qualifying comorbidities, and age — under penalty of perjury.
  5. CMS targets a decision within 72 hours of submission.
  6. Once approved, the patient fills the prescription in a 28- or 30-day supply. The patient pays $50. CMS pays the pharmacy the remainder through the Bridge processor.

The broader context

GLP-1 medications are increasingly going direct in the retail market. CNBC reported August 1 that as employers scale back GLP-1 coverage, patients are routing to Walmart, Costco, and Amazon pharmacy programs. For patients paying out of pocket, cash prices are substantial — Eli Lilly’s Foundayo starts at $149 per month for the lowest dose through LillyDirect. The Bridge, at $50 for qualifying Medicare patients, represents a meaningfully lower out-of-pocket cost for those who are eligible.

The Bridge is explicitly a stepping stone. CMS designed it to collect utilization data ahead of a broader Part D GLP-1 payment model — the BALANCE Model. CMS’s current Bridge page describes Part D implementation of BALANCE as “potential” rather than scheduled, and the Bridge’s extension through December 2027 reflects that the broader model is not yet on a firm timeline. Whether the BALANCE Model maintains the non-enrollment prescriber rule, expands coverage, or changes patient eligibility is not yet settled. The Bridge is the data-gathering phase.

What This Means

The Medicare GLP-1 Bridge is an 18-month demonstration — July 2026 through December 2027 — not a permanent Medicare benefit. What it does right now is create a coverage pathway for GLP-1 weight management that DPC physicians can write into — no enrollment step, no prior CMS relationship required.

The clinical management GLP-1 patients need — titration, side-effect monitoring, nutritional support, adjusting for comorbidities, tracking cardiovascular markers — is longitudinal primary care. That’s what a DPC membership is built for. The Bridge adds Medicare coverage of the medication itself.

If you see Medicare patients in your DPC practice who meet the weight and clinical criteria, don’t have a disqualifying diagnosis, and haven’t previously received a GLP-1 through their Part D plan, they may qualify now. The prescription process starts with a clinical conversation. The PA step — submitting attestation of the clinical criteria after the pharmacy’s initial denial — is what secures Bridge coverage approval and the $50 copay for the patient.